Read + Share
Printz C. Drug shows significant early promise in early, high-risk, HR-positive,
HER2-negative breast cancer: Interim data indicate that adding abemaciclib to
hormonal therapy reduces recurrence risk. Cancer 2021;127:169-170.
PMID: 33410514
|
 |
|
